Now showing items 1-2 of 2

    • Coexpression of nos2 and cox2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer 

      Basudhar, Debashree; Glynn, Sharon A.; Greer, Madison; Somasundaram, Veena; No, Jae Hong; Scheiblin, David A.; Garrido, Pablo; Heinz, William F.; Ryan, Aideen E.; Weiss, Jonathan M.; Cheng, Robert Y. S.; Ridnour, Lisa A.; Lockett, Stephen J.; McVicar, Daniel W.; Ambs, Stefan; Wink, David A. (Proceedings of the National Academy of Sciences, 2017-10-27)
      Proinflammatory signaling pathways are commonly up-regulated in breast cancer. In estrogen receptor-negative (ER-) and triple-negative breast cancer (TNBC), nitric oxide synthase-2 (NOS2) and cyclooxygenase-2 (COX2) have ...
    • Gene expression profiles of no- and hno-donor treated breast cancer cells: insights into tumor response and resistance pathways 

      Cheng, Robert Y.S.; Basudhar, Debashree; Ridnour, Lisa A.; Heinecke, Julie L.; Kesarwala, Aparna H.; Glynn, Sharon; Switzer, Christopher H.; Ambs, Stefan; Miranda, Katrina M.; Wink, David A. (Elsevier BV, 2014-12-01)
      Nitric oxide (NO) synthase 2 (NOS2), a major inflammatory protein, modulates disease progression via NO in a number of pathologies, including cancer. The role of NOS2-derived NO is not only flux-dependent, which is higher ...